

Trial to compare the efficacy and safety of NNC195-0092 with placebo and Norditropin Flex Pro in Adults with growth hormone deficiency.

Principal Investigator	Peter J. Snyder MD
Study Title:	Trial to compare the efficacy and safety of NNC195-0092 with placebo and Norditropin Flex Pro in Adults with growth hormone deficiency.
Purpose:	The purpose of this study is to demonstrate the efficacy of once weekly dosing of NNC195-0092 compared to placebo and once daily dosing of somatropin after 35 weeks of treatment in adults with growth hormone deficiency.
Brief Description	This study consists of a 2-3 week screening period to evaluate requirements for the study, a 35 week main trial period followed by a 53 week extension period for a total of 88 weeks.
Eligibility	-23-79 years of age -human growth hormone treatment naive or no exposure for at least 180 days -confirmed growth hormone deficiency
Compensation (if applicable)	\$25 per visit to help cover transportation costs
Name	Eileen Markmann
Phone	(215) 898-5664
Email:	eileen.markmann@uphs.upenn.edu